WINDLAS BIOTECH LIMITED (WINDLAS) financials

WINDLAS BIOTECH LIMITED (WINDLAS) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.[1]

Market Cap: ₹1,906Cr.
Current Price: ₹924
Stock P/E: 28.7
ROE: 12.2%
ROCE: 15.9%
Book Value: ₹275
Dividend Yield: 0.68%
52W High / Low: ₹1,182/697

In Jun 2026, WINDLAS BIOTECH LIMITED (WINDLAS) reported sales ₹248 Cr and net profit ₹18 Cr.

Annual TTM: sales ₹942 Cr, net profit ₹66 Cr.

Shareholding: Promoters 63.31% (Jun 2026), FIIs 2.04% (Jun 2026), DIIs 9.84% (Jun 2026), Public 24.80% (Jun 2026), No. of Shareholders 44,996% (Jun 2026).

WINDLAS quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	187	195	203	210	222	233	238	248
Expenses	164	170	177	184	194	209	213	221
Operating Profit	23	25	26	27	29	24	25	27
OPM %	12%	13%	13%	13%	13%	10%	11%	11%
Other Income	5	4	5	5	4	5	4	5
Interest	1	1	1	1	1	1	1	2
Depreciation	6	7	8	7	8	8	8	7
Profit before tax	20	20	21	23	24	20	20	23
Tax %	23%	24%	22%	24%	25%	25%	21%	23%
Net Profit	16	15	16	18	18	15	16	18
EPS in Rs	7.49	7.29	7.77	8.43	8.45	7.09	7.59	8.55
Raw PDF	—	—	—	—	—	—	—	—

WINDLAS profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	329	428	466	513	631	760	904	942
Expenses	288	373	413	453	553	666	799	837
Operating Profit	41	55	53	60	78	94	105	105
OPM %	12%	13%	11%	12%	12%	12%	12%	11%
Other Income	1	-29	7	10	13	18	18	18
Interest	2	1	1	1	1	4	5	5
Depreciation	9	13	12	12	13	28	31	31
Profit before tax	31	11	46	57	77	79	87	87
Tax %	27%	55%	16%	25%	25%	24%	24%	—
Net Profit	22	5	39	43	58	61	66	66
EPS in Rs	12.34	2.75	17.69	20.05	27.95	28.94	31.48	31.68
Dividend Payout %	0%	0%	20%	20%	20%	20%	20%	—

WINDLAS balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	6	6	6	11	10	10	10	11
Reserves	188	210	193	384	392	440	495	570
Borrowings	30	27	32	7	5	4	33	35
Other Liabilities	73	100	65	89	121	172	222	291
Total Liabilities	297	344	296	491	529	626	760	907
Fixed Assets	62	68	96	91	109	179	223	213
CWIP	5	0	0	8	15	6	5	60
Investments	121	121	23	65	107	173	223	268
Other Assets	110	154	177	327	298	268	308	366
Total Assets	297	344	296	491	529	626	760	907

WINDLAS cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	22	21	11	9	61	109	68	105
Cash from Investing Activity	-7	-9	-20	-154	-14	-92	-74	-92
Cash from Financing Activity	-8	-6	1	130	-44	-15	1	-13
Net Cash Flow	7	5	-8	-15	3	2	-5	0
Free Cash Flow	12	11	6	-6	-9	71	16	37
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	80%	84%	33%	34%	117%	163%	95%	115%

WINDLAS shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	62.51%	62.51%	62.34%	62.34%	61.98%	61.98%	61.90%	63.31%
FIIs	2.00%	1.55%	1.52%	1.44%	1.11%	0.93%	0.60%	2.04%
DIIs	9.58%	10.26%	10.89%	11.22%	11.44%	11.44%	11.80%	9.84%
Public	25.91%	25.67%	25.25%	25.01%	25.48%	25.64%	25.69%	24.80%
No. of Shareholders	45,706	46,590	46,383	45,887	45,433	45,461	44,769	44,996

WINDLAS key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	79	72	68	87	83	79	80	92
Inventory Days	38	85	55	71	84	57	63	40
Days Payable	117	143	53	76	98	121	138	156
Cash Conversion Cycle	0	13	70	82	69	15	6	-24
Working Capital Days	-12	3	40	86	72	32	18	14
ROCE %	18%	14%	19%	15%	14%	18%	17%	16%

WINDLASUpdated 16 Oct 2026, 9:09

Windlas Biotech Limited

WINDLASUpdated 16 Oct 2026, 9:09

Market Cap

₹1,906Cr.

Current Price

₹924

High / Low

₹1,182/697

Stock P/E

28.7

ROE12.2%

ROCE15.9%

Book Value₹275

Face Value₹5.00

Dividend Yield0.68%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	145	0	128	3	3	16	26	12	5.8
Sep 2023	153	0	134	3	3	18	23	14	6.75
Dec 2023	162	0	142	3	3	20	24	15	7.26
Mar 2024	171	0	149	4	4	23	25	17	8.15
Jun 2024	175	0	154	4	6	18	26	13	6.45
Sep 2024	187	1	164	5	6	20	23	16	7.49
Dec 2024	195	1	170	4	7	20	24	15	7.29
Mar 2025	203	1	177	5	8	21	22	16	7.77
Jun 2025	210	1	184	5	7	23	24	18	8.43
Sep 2025	222	1	194	4	8	24	25	18	8.45
Dec 2025	233	1	209	5	8	20	25	15	7.09
Mar 2026	238	1	213	4	8	20	21	16	7.59
Jun 2026	248	2	221	5	7	23	23	18	8.55

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2016	274	7	253	1	9	6	20	5	2.86
Mar 2017	315	5	290	4	9	14	35	9	5.77
Mar 2018	320	5	284	5	11	25	33	17	10.63
Mar 2019	288	4	244	2	8	35	36	22	12.35
Mar 2020	329	2	288	1	9	31	27	22	12.34
Mar 2021	428	1	373	-29	13	11	55	5	2.75
Mar 2022	466	1	413	7	12	46	16	39	17.69
Mar 2023	513	1	453	10	12	57	25	43	20.05
Mar 2024	631	1	553	13	13	77	25	58	27.95
Mar 2025	760	4	666	18	28	79	24	61	28.94
Mar 2026	904	5	799	18	31	87	24	66	31.48
TTM	942	5	837	18	31	87	—	66	31.68

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	63.31%
FIIs	2.04%
DIIs	9.84%
Public	24.8%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	62.82%	0.8%	11.52%	24.85%
Dec 2023	62.82%	1.35%	11.71%	24.11%
Mar 2024	62.82%	1.18%	11.82%	24.19%
Jun 2024	62.51%	1.59%	10.35%	25.55%
Sep 2024	62.51%	2%	9.58%	25.91%
Dec 2024	62.51%	1.55%	10.26%	25.67%
Mar 2025	62.34%	1.52%	10.89%	25.25%
Jun 2025	62.34%	1.44%	11.22%	25.01%
Sep 2025	61.98%	1.11%	11.44%	25.48%
Dec 2025	61.98%	0.93%	11.44%	25.64%
Mar 2026	61.9%	0.6%	11.8%	25.69%
Jun 2026	63.31%	2.04%	9.84%	24.8%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2016	6	132	53	90	281	56	9	95	121	281
Mar 2017	6	141	62	94	304	56	15	121	111	304
Mar 2018	6	158	43	93	299	58	11	123	107	299
Mar 2019	6	188	30	73	297	62	5	121	110	297
Mar 2020	6	210	27	100	344	68	0	121	154	344
Mar 2021	6	193	32	65	296	96	0	23	177	296
Mar 2022	11	384	7	89	491	91	8	65	327	491
Mar 2023	10	392	5	121	529	109	15	107	298	529
Mar 2024	10	440	4	172	626	179	6	173	268	626
Mar 2025	10	495	33	222	760	223	5	223	308	760
Mar 2026	11	570	35	291	907	213	60	268	366	907

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2016	47	-62	38	24
Mar 2017	7	-39	5	-27
Mar 2018	39	-11	-25	4
Mar 2019	22	-7	-8	7
Mar 2020	21	-9	-6	5
Mar 2021	11	-20	1	-8
Mar 2022	9	-154	130	-15
Mar 2023	61	-14	-44	3
Mar 2024	109	-92	-15	2
Mar 2025	68	-74	1	-5
Mar 2026	105	-92	-13	0

Key ratios

Historical financial ratios

Category	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	74	70	68	79	72	68	87	83	79	80	92
Inventory Days	49	62	44	38	85	55	71	84	57	63	40
Days Payable	137	120	124	117	143	53	76	98	121	138	156
Cash Conversion Cycle	-14	13	-12	0	13	70	82	69	15	6	-24
Working Capital Days	-46	-37	2	-12	3	40	86	72	32	18	14
ROCE %	—	10%	13%	18%	14%	19%	15%	14%	18%	17%	16%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of WINDLAS BIOTECH LIMITED (WINDLAS)?

The reported market capitalisation for WINDLAS BIOTECH LIMITED (WINDLAS) is ₹1,906Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of WINDLAS?

The current price shown for WINDLAS BIOTECH LIMITED (WINDLAS) on Fincrux is ₹924 with a 52-week high/low of ₹1,182/697.

What is the P/E ratio of WINDLAS BIOTECH LIMITED (WINDLAS)?

The stock P/E for WINDLAS BIOTECH LIMITED (WINDLAS) is 28.7 on Fincrux, with ROE at 12.2% and ROCE at 15.9%.

What were WINDLAS latest quarterly results?

For Jun 2026, WINDLAS BIOTECH LIMITED (WINDLAS) reported sales ₹248 Cr and net profit ₹18 Cr (figures in ₹ crore unless noted).

What are WINDLAS annual sales and net profit?

For TTM, WINDLAS BIOTECH LIMITED (WINDLAS) shows sales of ₹942 Cr and net profit of ₹66 Cr on the Fincrux profit & loss statement.

Who owns WINDLAS BIOTECH LIMITED (WINDLAS)?

Latest shareholding for WINDLAS BIOTECH LIMITED (WINDLAS) on Fincrux: Promoters 63.31% (Jun 2026), FIIs 2.04% (Jun 2026), DIIs 9.84% (Jun 2026), Public 24.80% (Jun 2026), No. of Shareholders 44,996% (Jun 2026).

Where can I find WINDLAS BIOTECH LIMITED (WINDLAS) financials?

WINDLAS BIOTECH LIMITED (WINDLAS) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show WINDLAS balance sheet and cash flow?

Yes. The WINDLAS BIOTECH LIMITED (WINDLAS) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 16 October 2026 at 9:09